UCB: stock up after broker comments
(CercleFinance.com) - The stock of Belgian pharma group UCB closed up 3% yesterday after announcing in the morning that it expects total 2022 revenue at the top end of the guidance initially posted of 5.
3 to 5.4 billion euros.
Oddo says that both the consensus and its own estimates were initially at the lower end of this guidance, at 5.32 billion and 5.3 billion euros respectively.
Oddo adds that the group therefore also considers that its margin for 2022 should be at the top end of its guidance, i.e. a margin of 21% to 22%.
Oddo confirms its Outperform rating on the stock, along with a target price of 98 euros.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.